The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $297,872 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to Numentus Technologies Inc., a for-profit organization focused on advanced biomedical and diagnostic technology development. The funding will support the development of a Rapid and Versatile Quantitative PCR (RVPCR) instrument capable of providing high-speed, versatile PCR testing comparable to conventional benchtop thermal cyclers. The project aims to create an innovative PCR platform that can achieve the functionality of traditional PCR instruments while offering substantial improvements in speed, cost, and portability. Testing will target the detection of respiratory viruses, including SARS-CoV-2, influenza A, and influenza B. This project builds on Numentus Technologies' prior work in optical heating methods for PCR and leverages recent technological advancements to enhance PCR performance. The award has an ultimate completion date of January 31, 2025.
Generated 1/28/25, 10:48 AM